DOWNSTREAM PROCESSING FEATURED ARTICLES
AET BioTech, the separate biosimilars business within the generic drug developer AET (Alfred E Tiefenbacher) Group and BioXpress Therapeutics SA, a Swiss-based biotechnology company developing monoclonal antibody (MAb) biosimilars have entered into an agreement for the co-development of a biosimilar version of the TNF inhibitor MAb Adalimumab.
-
Research Breakthrough Selectively Represses The Immune System
In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin -- the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.
-
Lonza And OncoMed Pharmaceuticals Sign A Process Development And Manufacturing Collaboration And Multi-Product GS License Agreement For Anti-Cancer Therapeutics
Lonza, a global leader in biological manufacturing and OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced recently an agreement for the development and manufacture of OncoMed’s pipeline of anti-cancer stem cell therapeutics.
-
Forsyth Scientists Define The Bacteria That Live In The Mouth, Throat, And Gut
For the first time, scientists have defined the bacteria that inhabit multiple sites along the healthy human digestive tract in a large number of individuals. To prevent and control bacterial diseases, it is essential to first identify which bacteria are responsible for keeping us in good health.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Rapid Chemically-Defined Feed Media Development to Improve Simulated Cell Culture Processes
Implementing an optimized feed medium may be the most effective alternative for modifications to the growth medium in an existing process.
-
Optimized Purity And Recovery Of A Monoclonal Antibody Using Mixed-Mode Chromatography Media
Monoclonal antibodies (mAbs) remain a predominant class of therapeutic protein products on the market because of their wide range of applications in disease treatment and diagnosis. Over the years, upstream technology advancements have helped improve the titer of target antibodies, from merely 1 g/L two decades ago to 10–13 g/L in fed-batch processes and up to 25 g/L in perfusion cultures today (Gronemeyer et al. 2014).
-
Mammalian Virus Purification Using Ceramic Hydroxyapatite
Conventional techniques for mammalian virus purification produce variable quality, quantity, and significant loss of particle infectivity. We propose the chromatographic separation of viral particles of diverse sizes and from different families such as dengue, influenza, mouse hepatitis, adenovirus, poliovirus using CHT Ceramic Hydroxyapatite resin.
-
Micro-Volume Determination Of Labeling Efficiency In A Standard Microplate Reader
A variety of methods and reagents have been developed to efficiently label biomolecules. By Peter J. Brescia, Applications Scientist, BioTek Instruments, Inc.
-
Single-Use Connections Advance Aseptic Processing
John Boehm discusses how single-use connections advance aseptic processing and create increased process flexibility and reliability while reducing costs.
-
Avoiding Drug Shortages With Microbial Detection
Over the past year, critical drug shortages used to treat a host of life-threatening illnesses have been making headlines. Microbial contamination has been cited as a major contributor to the shortage, yet the prevailing practices to ensure the safety of drugs have been slow to change. In most cases, quality assurance practices safeguarding the drug making environment continue to rely on periodic air and a culturing method from a prior century. By Aric Meares, President and CEO, BioVigilant